Cargando…

The Interplay of Type 1, Type 2, and Type 3 Lymphocytes and Cytokines in Atopic Dermatitis

Atopic dermatitis (AD) is classified as a type 2 disease owing to the majority of type 2 lymphocytes that constitute the skin-infiltrating leukocytes. However, all of the type 1–3 lymphocytes intermingle in inflamed skin lesions. Here, using an AD mouse model where caspase-1 was specifically amplifi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamanaka, Keiichi, Kono, Yui, Iida, Shohei, Nakanishi, Takehisa, Nishimura, Mai, Matsushima, Yoshiaki, Kondo, Makoto, Habe, Koji, Imai, Yasutomo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960233/
https://www.ncbi.nlm.nih.gov/pubmed/36834723
http://dx.doi.org/10.3390/ijms24043310
_version_ 1784895464267579392
author Yamanaka, Keiichi
Kono, Yui
Iida, Shohei
Nakanishi, Takehisa
Nishimura, Mai
Matsushima, Yoshiaki
Kondo, Makoto
Habe, Koji
Imai, Yasutomo
author_facet Yamanaka, Keiichi
Kono, Yui
Iida, Shohei
Nakanishi, Takehisa
Nishimura, Mai
Matsushima, Yoshiaki
Kondo, Makoto
Habe, Koji
Imai, Yasutomo
author_sort Yamanaka, Keiichi
collection PubMed
description Atopic dermatitis (AD) is classified as a type 2 disease owing to the majority of type 2 lymphocytes that constitute the skin-infiltrating leukocytes. However, all of the type 1–3 lymphocytes intermingle in inflamed skin lesions. Here, using an AD mouse model where caspase-1 was specifically amplified under keratin-14 induction, we analyzed the sequential changes in type 1–3 inflammatory cytokines in lymphocytes purified from the cervical lymph nodes. Cells were cultured and stained for CD4, CD8, and γδTCR, followed by intracellular cytokines. Cytokine production in innate lymphocyte cells (ILCs) and the protein expression of type 2 cytokine IL-17E (IL-25) were investigated. We observed that, as inflammation progresses, the cytokine-producing T cells increased and abundant IL-13 but low levels of IL-4 are produced in CD4-positive T cells and ILCs. TNF-α and IFN-γ levels increased continuously. The total number of T cells and ILCs peaked at 4 months and decreased in the chronic phase. In addition, IL-25 may be simultaneously produced by IL-17F-producing cells. IL-25-producing cells increased in a time-dependent manner during the chronic phase and may work specifically for the prolongation of type 2 inflammation. Altogether, these findings suggest that inhibition of IL-25 may be a potential target in the treatment of inflammation.
format Online
Article
Text
id pubmed-9960233
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99602332023-02-26 The Interplay of Type 1, Type 2, and Type 3 Lymphocytes and Cytokines in Atopic Dermatitis Yamanaka, Keiichi Kono, Yui Iida, Shohei Nakanishi, Takehisa Nishimura, Mai Matsushima, Yoshiaki Kondo, Makoto Habe, Koji Imai, Yasutomo Int J Mol Sci Article Atopic dermatitis (AD) is classified as a type 2 disease owing to the majority of type 2 lymphocytes that constitute the skin-infiltrating leukocytes. However, all of the type 1–3 lymphocytes intermingle in inflamed skin lesions. Here, using an AD mouse model where caspase-1 was specifically amplified under keratin-14 induction, we analyzed the sequential changes in type 1–3 inflammatory cytokines in lymphocytes purified from the cervical lymph nodes. Cells were cultured and stained for CD4, CD8, and γδTCR, followed by intracellular cytokines. Cytokine production in innate lymphocyte cells (ILCs) and the protein expression of type 2 cytokine IL-17E (IL-25) were investigated. We observed that, as inflammation progresses, the cytokine-producing T cells increased and abundant IL-13 but low levels of IL-4 are produced in CD4-positive T cells and ILCs. TNF-α and IFN-γ levels increased continuously. The total number of T cells and ILCs peaked at 4 months and decreased in the chronic phase. In addition, IL-25 may be simultaneously produced by IL-17F-producing cells. IL-25-producing cells increased in a time-dependent manner during the chronic phase and may work specifically for the prolongation of type 2 inflammation. Altogether, these findings suggest that inhibition of IL-25 may be a potential target in the treatment of inflammation. MDPI 2023-02-07 /pmc/articles/PMC9960233/ /pubmed/36834723 http://dx.doi.org/10.3390/ijms24043310 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yamanaka, Keiichi
Kono, Yui
Iida, Shohei
Nakanishi, Takehisa
Nishimura, Mai
Matsushima, Yoshiaki
Kondo, Makoto
Habe, Koji
Imai, Yasutomo
The Interplay of Type 1, Type 2, and Type 3 Lymphocytes and Cytokines in Atopic Dermatitis
title The Interplay of Type 1, Type 2, and Type 3 Lymphocytes and Cytokines in Atopic Dermatitis
title_full The Interplay of Type 1, Type 2, and Type 3 Lymphocytes and Cytokines in Atopic Dermatitis
title_fullStr The Interplay of Type 1, Type 2, and Type 3 Lymphocytes and Cytokines in Atopic Dermatitis
title_full_unstemmed The Interplay of Type 1, Type 2, and Type 3 Lymphocytes and Cytokines in Atopic Dermatitis
title_short The Interplay of Type 1, Type 2, and Type 3 Lymphocytes and Cytokines in Atopic Dermatitis
title_sort interplay of type 1, type 2, and type 3 lymphocytes and cytokines in atopic dermatitis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960233/
https://www.ncbi.nlm.nih.gov/pubmed/36834723
http://dx.doi.org/10.3390/ijms24043310
work_keys_str_mv AT yamanakakeiichi theinterplayoftype1type2andtype3lymphocytesandcytokinesinatopicdermatitis
AT konoyui theinterplayoftype1type2andtype3lymphocytesandcytokinesinatopicdermatitis
AT iidashohei theinterplayoftype1type2andtype3lymphocytesandcytokinesinatopicdermatitis
AT nakanishitakehisa theinterplayoftype1type2andtype3lymphocytesandcytokinesinatopicdermatitis
AT nishimuramai theinterplayoftype1type2andtype3lymphocytesandcytokinesinatopicdermatitis
AT matsushimayoshiaki theinterplayoftype1type2andtype3lymphocytesandcytokinesinatopicdermatitis
AT kondomakoto theinterplayoftype1type2andtype3lymphocytesandcytokinesinatopicdermatitis
AT habekoji theinterplayoftype1type2andtype3lymphocytesandcytokinesinatopicdermatitis
AT imaiyasutomo theinterplayoftype1type2andtype3lymphocytesandcytokinesinatopicdermatitis
AT yamanakakeiichi interplayoftype1type2andtype3lymphocytesandcytokinesinatopicdermatitis
AT konoyui interplayoftype1type2andtype3lymphocytesandcytokinesinatopicdermatitis
AT iidashohei interplayoftype1type2andtype3lymphocytesandcytokinesinatopicdermatitis
AT nakanishitakehisa interplayoftype1type2andtype3lymphocytesandcytokinesinatopicdermatitis
AT nishimuramai interplayoftype1type2andtype3lymphocytesandcytokinesinatopicdermatitis
AT matsushimayoshiaki interplayoftype1type2andtype3lymphocytesandcytokinesinatopicdermatitis
AT kondomakoto interplayoftype1type2andtype3lymphocytesandcytokinesinatopicdermatitis
AT habekoji interplayoftype1type2andtype3lymphocytesandcytokinesinatopicdermatitis
AT imaiyasutomo interplayoftype1type2andtype3lymphocytesandcytokinesinatopicdermatitis